337.05
0.06%
+0.10
Overview
News
Price History
Option Chain
Why SYK Down?
Discussions
Forecast
Stock Split
Dividend History
Stryker Corp. stock is currently priced at $337.05, with a 24-hour trading volume of 279.97K.
It has seen a +0.06% increased in the last 24 hours and a -3.72% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $336.1 pivot point. If it approaches the $338.9 resistance level, significant changes may occur.
Previous Close:
$337.15
Open:
$335.19
24h Volume:
279.97K
Market Cap:
$128.28B
Revenue:
$20.50B
Net Income/Loss:
$3.17B
P/E Ratio:
50.01
EPS:
6.74
Net Cash Flow:
$3.14B
1W Performance:
+3.66%
1M Performance:
-3.72%
6M Performance:
+30.46%
1Y Performance:
+12.90%
Stryker Corp. Stock (SYK) Company Profile
Name
Stryker Corp.
Sector
Industry
Phone
269-385-2600
Address
2825 Airview Boulevard, Kalamazoo, MI
Stryker Corp. Stock (SYK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-31-24 | Upgrade | Canaccord Genuity | Hold → Buy |
Oct-20-23 | Initiated | ROTH MKM | Buy |
Sep-05-23 | Upgrade | BofA Securities | Neutral → Buy |
Mar-29-23 | Initiated | UBS | Neutral |
Jan-25-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-01-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Jul-28-22 | Upgrade | Edward Jones | Hold → Buy |
Jul-21-22 | Downgrade | Deutsche Bank | Buy → Hold |
Jul-11-22 | Downgrade | BofA Securities | Buy → Neutral |
Apr-13-22 | Initiated | Truist | Hold |
Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Mar-15-22 | Resumed | Evercore ISI | Outperform |
Mar-02-22 | Resumed | BofA Securities | Buy |
Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-07-21 | Initiated | Loop Capital | Buy |
Sep-14-21 | Resumed | Raymond James | Mkt Perform |
Jul-28-21 | Upgrade | Northland Capital | Market Perform → Outperform |
Jun-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
May-25-21 | Initiated | Barclays | Underweight |
Oct-06-20 | Initiated | Northland Capital | Market Perform |
Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
Apr-13-20 | Downgrade | Barclays | Equal Weight → Underweight |
Apr-01-20 | Downgrade | Goldman | Buy → Sell |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Buy |
Jan-08-20 | Initiated | SunTrust | Hold |
Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-30-19 | Reiterated | BTIG Research | Buy |
Nov-05-19 | Downgrade | Barclays | Overweight → Equal Weight |
Oct-30-19 | Reiterated | BofA/Merrill | Buy |
Jul-02-19 | Downgrade | Evercore ISI | Outperform → In-line |
Jan-30-19 | Reiterated | Canaccord Genuity | Buy |
Jan-03-19 | Initiated | Deutsche Bank | Buy |
Jan-02-19 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-16-18 | Initiated | Barclays | Overweight |
Aug-16-18 | Initiated | BTIG Research | Buy |
Jun-27-18 | Initiated | Bernstein | Mkt Perform |
Apr-27-18 | Reiterated | Stifel | Buy |
View All
Stryker Corp. Stock (SYK) Latest News
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Seeking Clues to Stryker (SYK) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Zacks Investment Research
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
Zacks Investment Research
Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings
Zacks Investment Research
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay
Zacks Investment Research
Stryker Corp. Stock (SYK) Financials Data
Stryker Corp. (SYK) Revenue 2024
SYK reported a revenue (TTM) of $20.50 billion for the quarter ending December 31, 2023, a +11.11% rise year-over-year.
Stryker Corp. (SYK) Net Income 2024
SYK net income (TTM) was $3.17 billion for the quarter ending December 31, 2023, a +34.22% increase year-over-year.
Stryker Corp. (SYK) Cash Flow 2024
SYK recorded a free cash flow (TTM) of $3.14 billion for the quarter ending December 31, 2023, a +54.03% increase year-over-year.
Stryker Corp. (SYK) Earnings per Share 2024
SYK earnings per share (TTM) was $8.25 for the quarter ending December 31, 2023, a +33.71% growth year-over-year.
Stryker Corp. Stock (SYK) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Stiles Spencer S | Group President |
Mar 21 '24 |
Option Exercise |
0.00 |
203 |
0 |
55,602 |
Pierce James Andrew | Group President |
Mar 21 '24 |
Option Exercise |
0.00 |
203 |
0 |
60,664 |
Menon Viju | Group President |
Mar 21 '24 |
Option Exercise |
0.00 |
158 |
0 |
13,762 |
Lobo Kevin | Chair and CEO |
Mar 21 '24 |
Option Exercise |
0.00 |
905 |
0 |
119,719 |
Fletcher Robert S | VP, Chief Legal Officer |
Mar 21 '24 |
Option Exercise |
0.00 |
120 |
0 |
13,143 |
Fink M Kathryn | VP, Chief HR Officer |
Mar 21 '24 |
Option Exercise |
0.00 |
83 |
0 |
13,710 |
Boehnlein Glenn S | VP, Chief Financial Officer |
Mar 21 '24 |
Option Exercise |
0.00 |
256 |
0 |
31,152 |
Becker Yin C | VP, Chief Corp Affairs Officer |
Mar 21 '24 |
Option Exercise |
0.00 |
36 |
0 |
29,898 |
Berry William E Jr | VP, Chief Accounting Officer |
Mar 08 '24 |
Option Exercise |
154.14 |
1,480 |
228,127 |
5,155 |
Berry William E Jr | VP, Chief Accounting Officer |
Mar 07 '24 |
Option Exercise |
108.30 |
17,660 |
1,912,588 |
21,335 |
About Stryker Corp.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Cap:
|
Volume (24h):